Recently, China's National Food and Drug Administration (NMPA) announced that Aidi Pharmaceuticals' national class 1 new drug Abond® (Ainovirin Tablets) (ACC007) has been officially approved. In July 2020, the New Drug Marketing Application (NDA) of Albond® was accepted by the CDE and was subsequently included in the priority review. This is the first national Class 1 anti-AIDS drug approved by Aidi Pharmaceuticals, and it has been included in the National 13th Five-Year "Major New Drug Development" major science and technology project, and its indication is the treatment of HIV-1 infection.

Ainuovirine is a HIV-1 non-nucleoside reverse transcriptase inhibitor that inhibits the replication of HIV-1 through non-competitive binding of HIV-1 reverse transcriptase. The listing of this variety provides a new treatment option for HIV-1 infected patients.

Enovirin is the first class 1 new anti-AIDS drug in Aidi Pharmaceuticals. The results of the phase III clinical study show that its antiviral effectiveness is equivalent to efavirenz; it has excellent safety performance and can significantly improve the side effects of the central nervous system. , Lower side effects on liver cells, significantly improve blood lipid biochemical indicators, and reduce the incidence of skin rashes. Aidi Pharmaceuticals mentioned in the 2020 annual report that after the launch of Ainovirin, it is expected to fill the gap of domestically-made innovative drugs in this segment and effectively improve the accessibility of advanced clinical drugs.

Aidi Pharmaceuticals entered the Sci-tech Innovation Board on July 20, 2020, targeting AIDS, inflammation and malignant tumors and other major diseases that seriously threaten human health. Its existing sales products include human-derived protein raw materials, medicines, and HIV diagnostic equipment and reagents. .

In the field of AIDS treatment, in addition to the newly approved Ainovirin, Aidi Pharmaceuticals also has the anti-AIDS triple single-tablet compound preparation ACC008 under development. This is based on Anovrin, combined with 2 nucleosides to reverse Recording enzyme inhibitors (lamivudine and tenofovir) developed the first three-in-one single-tablet compound innovative drug preparation in China. The drug has also been approved for clinical trials in newly-treated and treated patients.

AIDS is a serious disease caused by HIV infection. It was once considered a deadly disease with no cure. It is reported that by 2020, about 37.6 million people worldwide will be infected with HIV, and about 1.5 million people will be newly infected with HIV in 2020.

Innovative anti-HIV drugs are relatively scarce in my country. At present, most of the pipeline products under research in China are still in the early clinical stage and have great uncertainty. The only domestic innovative drug that has been on the market is Abvette, but it is significantly different from Albond® in terms of indications, route of administration and patient groups. The number of innovative drugs against HIV infection in China is relatively small and most of them are in the early clinical stage. After the launch of Aibond®, it is expected to give full play to its advantages, realize the optimization and upgrade of treatment plans, and better improve the quality of life of patients.

The launch of Aidi's Class 1 new drug Ainovirin tablets will provide a new treatment option for Chinese AIDS patients, which undoubtedly meets the urgent needs of domestic AIDS treatment, optimizes and upgrades treatment plans, and better improves patients Quality of Life. .